OAIC Supported Studies
Pharmacological Intervention in the Elderly Phase 2 (PIE 2)
Contact: | Phone: |
Dalane Kitzman, MD | 336-716-3274 |
The primary aim of this study is to conduct a randomized, controlled, double-blind trial of the generic aldosterone antagonist spironolactone in 80 patients with isolated DHF in order to test the following primary hypothesis: Aldosterone antagonism will improve exercise tolerance and quality of life in elderly patients with diastolic heart failure. This study will examine the role of aldosterone activation in the pathophysiology of exercise intolerance in elderly patients with DHF, determine whether spironolactone, a generic, inexpensive aldosterone antagonist can improve exercise tolerance, and evaluate the potential mechanisms by which this may occur. These results are important because DHF affects more than 2.1 million older Americans, and exercise intolerance is a potentially modifiable outcome that is a major determinant of quality of life and disability in these patients.
Enrollment and intervention on-going.
